ECSP088398A - Compuestos tricíclicos útiles como agonistas de receptores de oxitocina - Google Patents

Compuestos tricíclicos útiles como agonistas de receptores de oxitocina

Info

Publication number
ECSP088398A
ECSP088398A EC2008008398A ECSP088398A ECSP088398A EC SP088398 A ECSP088398 A EC SP088398A EC 2008008398 A EC2008008398 A EC 2008008398A EC SP088398 A ECSP088398 A EC SP088398A EC SP088398 A ECSP088398 A EC SP088398A
Authority
EC
Ecuador
Prior art keywords
oxychocine
tricyclic compounds
receptors agonists
useful tricyclic
useful
Prior art date
Application number
EC2008008398A
Other languages
English (en)
Inventor
Lynn Resnick
Zia Rahman
Sharon Joy Rosenzweig-Lipson
Robert H Ring
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088398A publication Critical patent/ECSP088398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen aquí métodos para tratar y prevenir la ansiedad, trastornos relacionados con la ansiedad, esquizofrenia y trastornos relacionados con la esquizofrenia, donde dichos métodos comprenden la administración de agonistas del receptor de oxitocina: de fórmula 1, o una sal farmacéuticamente aceptable de los mismos, donde: G1 es (I); de fórmula 2 o una sal farmacéuticamente de los mismos, donde: G2 es (II).
EC2008008398A 2005-10-24 2008-04-24 Compuestos tricíclicos útiles como agonistas de receptores de oxitocina ECSP088398A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72965605P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
ECSP088398A true ECSP088398A (es) 2008-06-30

Family

ID=37834124

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008398A ECSP088398A (es) 2005-10-24 2008-04-24 Compuestos tricíclicos útiles como agonistas de receptores de oxitocina

Country Status (15)

Country Link
US (1) US20070117794A1 (es)
EP (1) EP1948662A2 (es)
JP (1) JP2009512730A (es)
KR (1) KR20080063848A (es)
CN (1) CN101296929A (es)
AU (1) AU2006306547A1 (es)
BR (1) BRPI0617770A2 (es)
CA (1) CA2626180A1 (es)
CR (1) CR9923A (es)
EC (1) ECSP088398A (es)
GT (1) GT200800052A (es)
IL (1) IL190900A0 (es)
NO (1) NO20081835L (es)
RU (1) RU2008114374A (es)
WO (1) WO2007050353A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
EP2571511B1 (en) 2010-05-18 2014-10-08 Université de Genève New uses of oxytocin-like molecules and related methods
WO2011146806A1 (en) * 2010-05-21 2011-11-24 University Of Florida Research Foundation, Inc. Methods for reducing anesthetic-inducible epileptogenic and neurotoxic effects
US9585935B2 (en) * 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia
US10265372B2 (en) 2014-08-12 2019-04-23 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
US11033555B2 (en) * 2015-07-06 2021-06-15 Kinoxis Therapeutics Pty Ltd Therapeutic compounds and compositions for treating social disorders and substance use disorders
AU2017377653B2 (en) * 2016-12-12 2022-04-21 Kinoxis Therapeutics Pty Ltd Non-peptide oxytocin receptor agonists
CN111867632B (zh) 2018-03-23 2024-08-16 赛途公司 骨骼肌肥大诱导剂的alk5抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900200B2 (en) * 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists

Also Published As

Publication number Publication date
WO2007050353A2 (en) 2007-05-03
CA2626180A1 (en) 2007-05-03
CR9923A (es) 2008-06-27
BRPI0617770A2 (pt) 2011-08-09
IL190900A0 (en) 2008-11-03
NO20081835L (no) 2008-05-20
WO2007050353A3 (en) 2007-06-21
JP2009512730A (ja) 2009-03-26
CN101296929A (zh) 2008-10-29
EP1948662A2 (en) 2008-07-30
KR20080063848A (ko) 2008-07-07
AU2006306547A1 (en) 2007-05-03
RU2008114374A (ru) 2009-12-10
US20070117794A1 (en) 2007-05-24
GT200800052A (es) 2008-10-06

Similar Documents

Publication Publication Date Title
ECSP088398A (es) Compuestos tricíclicos útiles como agonistas de receptores de oxitocina
ECSP066520A (es) Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
DOP2006000170A (es) Nuevos derivados de espirocromanona
UY29184A1 (es) Derivados de sulfonilbencimidazol
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY31430A1 (es) Derivados de piridina y pirazina -83
DE602005023197D1 (de) -muscarinrezeptors
NO20075641L (no) Kroman og kromenderivater og ders anvendelse
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO5261529A1 (es) Uso de antagonistas selectivos de receptores de tipo 4(ep4) de la prostaglandina pde2 para el tratamiento de la insuficiencia renal aguda y cronica
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
UY28150A1 (es) Agentes terapeuticos
PA8591701A1 (es) Derivados de pirrolopirimidina
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
MX2007005199A (es) Indolizinas sustituidas y derivados como agentes del sistema nervioso central.